Cyclo(Phe-Gly)

CAS No. 5037-75-2

Cyclo(Phe-Gly)( —— )

Catalog No. M31141 CAS No. 5037-75-2

Cyclo(Phe-Gly) shows weak antagonistic activity against VEGFR2 -CD, it also shows strong inhibitory activity against human cancer cells(KB,KBv200) with LD50 at 6.5 and 11.2 umol/L,respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 657 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cyclo(Phe-Gly)
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyclo(Phe-Gly) shows weak antagonistic activity against VEGFR2 -CD, it also shows strong inhibitory activity against human cancer cells(KB,KBv200) with LD50 at 6.5 and 11.2 umol/L,respectively.
  • Description
    Cyclo(Phe-Gly) shows weak antagonistic activity against VEGFR2 -CD, it also shows strong inhibitory activity against human cancer cells(KB,KBv200) with LD50 at 6.5 and 11.2 umol/L,respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    5037-75-2
  • Formula Weight
    204.23
  • Molecular Formula
    C11H12N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Z433927330

    Z433927330 is a potent and selective Aquaporin-7 (AQP7) inhibitor(IC50s of 0.2).Z433927330 inhibits glycerol permeability(IC50 : 0.6 μM).

  • 1,2-Dimyristoyl-sn-g...

    1,2-dimyristoyl-sn-glycerol is able to increase AChE activity by 35-40% at concentrations of 25 micrograms/ml in the parasite S. mansoni..

  • Inotuzumab

    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22.